<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8390">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835237</url>
  </required_header>
  <id_info>
    <org_study_id>111413</org_study_id>
    <nct_id>NCT00835237</nct_id>
  </id_info>
  <brief_title>Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.</brief_title>
  <official_title>Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IIIb, observer-blind study will evaluate the immunogenicity and safety of GSK
      Biologicals' Boostrix® vaccine in adults (extending indication) aged 65 years or older.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value</measure>
    <time_frame>One month after vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibodies against vaccine antigens assessed were: anti-diphtheria (anti-D) and anti-tetanus (anti-T).
Anti-D antibody cut-off value assessed was ≥ 0.1 International Unit per milliliter (IU/mL)
Anti-T antibody cut-off values assessed were ≥ 0.1 IU/mL and ≥ 1.0 IU/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration</measure>
    <time_frame>Before (PRE) and one month after vaccination (POST)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentration for anti-PT, anti-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) units per millilitre (EL.U/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-T and Anti-D Antibody Concentrations</measure>
    <time_frame>Before (PRE) and one month after vaccination (POST)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concentrations for anti-T and anti-D antibodies given as GMC in IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Vaccine Response for Anti-T and Anti-D Antibodies Concentrations Above the Cut-off</measure>
    <time_frame>One month after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Booster response defined as :
For initially seronegative subjects (&lt; 0.1 IU/mL), antibody concentration ≥ 0.4 IU/mL one month after vaccination.
For initially seropositive subjects (≥ 0.1 IU/mL): antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off</measure>
    <time_frame>One month after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Booster response defined as :
For initially seronegative subjects (&lt; 5 EL.U/mL), antibody concentration ≥ 20 EL.U/mL one month after vaccination.
For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration &lt; 20 EL.U/mL: antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration.
For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration ≥ 20 EL.U/mL : antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off, Using Alternative Definitions.</measure>
    <time_frame>One month after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vaccine response defined as:
For initially seronegative subjects (&lt; 5 EL.U/mL ), antibody concentration ≥ 10 EL.U/mL one month after vaccination.
For initially seropositive subjects (≥ 5 EL.U/mL), antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Symptoms</measure>
    <time_frame>Within the 4-day (Day 0-3) post-vaccination period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited General Symptoms</measure>
    <time_frame>Within the 4-day (Day 0-3) post-vaccination period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed include fatigue, gastrointestinal symptoms, headache, and fever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AE)</measure>
    <time_frame>Within the 31-day (Day 0-30) post-vaccination period</time_frame>
    <safety_issue>No</safety_issue>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAE)</measure>
    <time_frame>From the vaccintation up to Day 182</time_frame>
    <safety_issue>No</safety_issue>
    <description>An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1332</enrollment>
  <condition>Diphtheria</condition>
  <condition>Pertussis</condition>
  <condition>Diphtheria-Tetanus-acellular Pertussis Vaccines</condition>
  <condition>Tetanus</condition>
  <arm_group>
    <arm_group_label>Boostrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decavac Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Boostrix®</intervention_name>
    <description>Intramuscular, single dose.</description>
    <arm_group_label>Boostrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Decavac™</intervention_name>
    <description>Intramuscular, single dose.</description>
    <arm_group_label>Decavac Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that can and will comply with the requirements
             of the protocol should be enrolled in the study.

          -  Males or females 65 years of age and older at the time of study entry.

          -  Free of an acute aggravation of the health status as established by medical history
             and medical history and clinical examination before entering into the study.

          -  Written informed consent from all subjects.

        Exclusion Criteria:

          -  Administration of a diphtheria-tetanus (Td) booster within the previous 5 years.

          -  Administration of a Tdap vaccine at any time prior to study entry.

          -  History of diphtheria and/or tetanus and/or pertussis disease.

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccines within 30 days preceding vaccination, or planned use during the entire study
             period.

          -  Administration of other licensed vaccines within 2 weeks (for inactivated vaccines)
             or 4 weeks (for live vaccines) prior to enrolment in this study, with the exception
             of influenza, vaccine, which may be administered at any time up to or during the
             study period, including the day of study vaccination.

          -  Planned administration of any vaccine not foreseen by the study protocol up to 30
             days following vaccination, with the exception of influenza, vaccine, which may be
             administered at any time up to or during the study period, including the day of study
             vaccination. Pneumococcal and zoster vaccines can be administered at the discretion
             of the investigator when the subject comes back at Visit 2.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to vaccination or planned administration during the study period.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination.

          -  History of serious allergic reaction following any other tetanus toxoid, diphtheria
             toxoid or pertussis-containing vaccine or any component of the study vaccines.

          -  History of encephalopathy within seven days of administration of a previous booster
             dose of pertussis vaccine that is not attributable to another identifiable cause.

          -  Progressive neurologic disorder, uncontrolled epilepsy or progressive encephalopathy:
             pertussis vaccine should not be administered to individuals with these conditions
             until a treatment regimen has been established and the condition has stabilized.

          -  Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by clinical evaluation or pre-existing
             laboratory screening tests.

          -  Acute disease at the time of vaccination.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding vaccination, or planned administration during the study period.

          -  Any medical condition that, in the opinion of the investigator, might interfere with
             the evaluations required by the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pratt</city>
        <state>Kansas</state>
        <zip>67124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mogadore</city>
        <state>Ohio</state>
        <zip>44260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wandsworth</city>
        <state>Ohio</state>
        <zip>44281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Williamsburg</city>
        <state>Virginia</state>
        <zip>23185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Weston WM, Friedland LR, Wu X, Howe B. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials. Vaccine. 2012 Feb 21;30(9):1721-8. doi: 10.1016/j.vaccine.2011.12.055. Epub 2011 Dec 31.</citation>
    <PMID>22212127</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>January 5, 2012</lastchanged_date>
  <firstreceived_date>February 2, 2009</firstreceived_date>
  <firstreceived_results_date>July 8, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>Boostrix®</keyword>
  <keyword>adults</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Boostrix Group</title>
          <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
        </group>
        <group group_id="P2">
          <title>Decavac Group</title>
          <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="887"/>
                <participants group_id="P2" count="445"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="881"/>
                <participants group_id="P2" count="445"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Boostrix Group</title>
          <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
        </group>
        <group group_id="B2">
          <title>Decavac Group</title>
          <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="887"/>
                <measurement group_id="B2" value="445"/>
                <measurement group_id="B3" value="1332"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="71.6" spread="5.35"/>
                <measurement group_id="B2" value="71.9" spread="5.62"/>
                <measurement group_id="B3" value="71.7" spread="5.44"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="478"/>
                <measurement group_id="B2" value="237"/>
                <measurement group_id="B3" value="715"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="409"/>
                <measurement group_id="B2" value="208"/>
                <measurement group_id="B3" value="617"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value</title>
        <description>Antibodies against vaccine antigens assessed were: anti-diphtheria (anti-D) and anti-tetanus (anti-T).
Anti-D antibody cut-off value assessed was ≥ 0.1 International Unit per milliliter (IU/mL)
Anti-T antibody cut-off values assessed were ≥ 0.1 IU/mL and ≥ 1.0 IU/mL</description>
        <time_frame>One month after vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Boostrix Group</title>
            <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Decavac Group</title>
            <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="864"/>
                  <measurement group_id="O2" value="439"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value</title>
            <description>Antibodies against vaccine antigens assessed were: anti-diphtheria (anti-D) and anti-tetanus (anti-T).
Anti-D antibody cut-off value assessed was ≥ 0.1 International Unit per milliliter (IU/mL)
Anti-T antibody cut-off values assessed were ≥ 0.1 IU/mL and ≥ 1.0 IU/mL</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-D (≥ 0.1 IU/mL) (N= 859;432)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="729"/>
                  <measurement group_id="O2" value="374"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-T (≥ 0.1 IU/mL) (N= 864;439)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="836"/>
                  <measurement group_id="O2" value="428"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-T (≥ 1.0 IU/mL) (N= 864;439)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="767"/>
                  <measurement group_id="O2" value="395"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-T and Anti-D Antibody Concentrations</title>
        <description>Concentrations for anti-T and anti-D antibodies given as GMC in IU/mL.</description>
        <time_frame>Before (PRE) and one month after vaccination (POST)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Boostrix Group</title>
            <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Decavac Group</title>
            <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="864"/>
                  <measurement group_id="O2" value="439"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-T and Anti-D Antibody Concentrations</title>
            <description>Concentrations for anti-T and anti-D antibodies given as GMC in IU/mL.</description>
            <units>IU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-D (PRE) (N=844;430)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.2" lower_limit="0.2" upper_limit="0.2"/>
                  <measurement group_id="O2" value="0.2" lower_limit="0.1" upper_limit="0.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-D (POST) (N=859;432)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.9" lower_limit="0.8" upper_limit="1.0"/>
                  <measurement group_id="O2" value="0.8" lower_limit="0.7" upper_limit="1.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-T (PRE) (N=864;439)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" lower_limit="0.6" upper_limit="0.7"/>
                  <measurement group_id="O2" value="0.6" lower_limit="0.5" upper_limit="0.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-T (POST) (N=864;439)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.0" lower_limit="3.6" upper_limit="4.3"/>
                  <measurement group_id="O2" value="7.1" lower_limit="6.1" upper_limit="8.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Vaccine Response for Anti-T and Anti-D Antibodies Concentrations Above the Cut-off</title>
        <description>Booster response defined as :
For initially seronegative subjects (&lt; 0.1 IU/mL), antibody concentration ≥ 0.4 IU/mL one month after vaccination.
For initially seropositive subjects (≥ 0.1 IU/mL): antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration.</description>
        <time_frame>One month after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Boostrix Group</title>
            <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Decavac Group</title>
            <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="863"/>
                  <measurement group_id="O2" value="439"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Vaccine Response for Anti-T and Anti-D Antibodies Concentrations Above the Cut-off</title>
            <description>Booster response defined as :
For initially seronegative subjects (&lt; 0.1 IU/mL), antibody concentration ≥ 0.4 IU/mL one month after vaccination.
For initially seropositive subjects (≥ 0.1 IU/mL): antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-D (N=842;428)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="383"/>
                  <measurement group_id="O2" value="189"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-T (N=863;439)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="438"/>
                  <measurement group_id="O2" value="306"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off</title>
        <description>Booster response defined as :
For initially seronegative subjects (&lt; 5 EL.U/mL), antibody concentration ≥ 20 EL.U/mL one month after vaccination.
For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration &lt; 20 EL.U/mL: antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration.
For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration ≥ 20 EL.U/mL : antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.</description>
        <time_frame>One month after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Boostrix Group</title>
            <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Decavac Group</title>
            <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="864"/>
                  <measurement group_id="O2" value="439"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off</title>
            <description>Booster response defined as :
For initially seronegative subjects (&lt; 5 EL.U/mL), antibody concentration ≥ 20 EL.U/mL one month after vaccination.
For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration &lt; 20 EL.U/mL: antibody concentration one month after vaccination ≥ 4 fold the pre-vaccination antibody concentration.
For initially seropositive subjects (≥ 5 EL.U/mL) with pre-vaccination antibody concentration ≥ 20 EL.U/mL : antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-PT (N=846;430)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="585"/>
                  <measurement group_id="O2" value="430"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-FHA (N=821;422)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="762"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-PRN (N=864;439)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="638"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off, Using Alternative Definitions.</title>
        <description>Vaccine response defined as:
For initially seronegative subjects (&lt; 5 EL.U/mL ), antibody concentration ≥ 10 EL.U/mL one month after vaccination.
For initially seropositive subjects (≥ 5 EL.U/mL), antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.</description>
        <time_frame>One month after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Boostrix Group</title>
            <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Decavac Group</title>
            <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="864"/>
                  <measurement group_id="O2" value="439"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Vaccine Response for Anti-PT, Anti-FHA and Anti-PRN Antibodies Concentrations Above the Cut-off, Using Alternative Definitions.</title>
            <description>Vaccine response defined as:
For initially seronegative subjects (&lt; 5 EL.U/mL ), antibody concentration ≥ 10 EL.U/mL one month after vaccination.
For initially seropositive subjects (≥ 5 EL.U/mL), antibody concentration one month after vaccination ≥ 2 fold the pre-vaccination antibody concentration.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-PT (N=846;430)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="699"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-FHA (N=821;422)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="765"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-PRN (N=864;439)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="714"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
        <time_frame>Within the 4-day (Day 0-3) post-vaccination period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Boostrix Group</title>
            <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Decavac Group</title>
            <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="882"/>
                  <measurement group_id="O2" value="445"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited Local Symptoms</title>
            <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="190"/>
                  <measurement group_id="O2" value="123"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include fatigue, gastrointestinal symptoms, headache, and fever</description>
        <time_frame>Within the 4-day (Day 0-3) post-vaccination period</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Boostrix Group</title>
            <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Decavac Group</title>
            <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="882"/>
                  <measurement group_id="O2" value="445"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited General Symptoms</title>
            <description>Solicited general symptoms assessed include fatigue, gastrointestinal symptoms, headache, and fever</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="110"/>
                  <measurement group_id="O2" value="66"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="101"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>Within the 31-day (Day 0-30) post-vaccination period</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Boostrix Group</title>
            <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Decavac Group</title>
            <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="887"/>
                  <measurement group_id="O2" value="445"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
            <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="152"/>
                  <measurement group_id="O2" value="64"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration</title>
        <description>Concentration for anti-PT, anti-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) units per millilitre (EL.U/mL)</description>
        <time_frame>Before (PRE) and one month after vaccination (POST)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for analysis of immunogenicity, on subjects with available results</population>
        <group_list>
          <group group_id="O1">
            <title>Boostrix Group</title>
            <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Decavac Group</title>
            <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="865"/>
                  <measurement group_id="O2" value="439"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibodies Concentration</title>
            <description>Concentration for anti-PT, anti-FHA and anti-PRN antibodies given as geometric mean concentration (GMC) in Enzyme-Linked Immuno Sorbent Assay (ELISA) units per millilitre (EL.U/mL)</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-PT (PRE) (N=859;433)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.6" lower_limit="6.1" upper_limit="7.1"/>
                  <measurement group_id="O2" value="6.5" lower_limit="5.8" upper_limit="7.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-PT (POST) (N=852;431)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49.1" lower_limit="44.9" upper_limit="53.7"/>
                  <measurement group_id="O2" value="6.4" lower_limit="5.8" upper_limit="7.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-FHA (PRE) (N=848;430)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50.2" lower_limit="46.2" upper_limit="54.5"/>
                  <measurement group_id="O2" value="44.3" lower_limit="39.5" upper_limit="49.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-FHA (POST) (N=835;428)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="689.0" lower_limit="638.8" upper_limit="743.1"/>
                  <measurement group_id="O2" value="44.4" lower_limit="39.7" upper_limit="49.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-PRN (PRE) (N=864;439)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.1" lower_limit="7.4" upper_limit="8.8"/>
                  <measurement group_id="O2" value="7.8" lower_limit="6.9" upper_limit="8.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-PRN (POST) (N=865;439)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="104.2" lower_limit="91.3" upper_limit="118.9"/>
                  <measurement group_id="O2" value="7.7" lower_limit="6.8" upper_limit="8.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
        <description>An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>From the vaccintation up to Day 182</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Boostrix Group</title>
            <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
          </group>
          <group group_id="O2">
            <title>Decavac Group</title>
            <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="887"/>
                  <measurement group_id="O2" value="445"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
            <description>An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Boostrix Group</title>
          <description>Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)</description>
        </group>
        <group group_id="E2">
          <title>Decavac Group</title>
          <description>Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Bone neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin’s lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Complicated migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="887"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
